Subsequently, Olive et al. confirmed the significant antitumor efficacy of RMC-7977 in preclinical models of pancreatic cancer and revealed that overexpression of YAP promotes resistance to RMC-7977 in pancreatic cancer 155. Here, YAP1 is linked to pancreatic neoplasm.